Opus Genetics, Inc
Clinical trials sponsored by Opus Genetics, Inc, explained in plain language.
-
Gene therapy injection aims to halt rare blindness
Disease control Recruiting nowThis early-stage trial tests a gene therapy called OPGx-BEST1 for two rare inherited eye diseases that cause vision loss. About 10 adults will receive a single injection into one eye to see if it is safe and to find the best dose. The study will follow participants for 5 years to…
Phase: PHASE1, PHASE2 • Sponsor: Opus Genetics, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Experimental gene injection aims to halt rare childhood blindness
Disease control Recruiting nowThis study tests a gene therapy called OPGx-001 for people with vision loss caused by LCA5 gene mutations. The treatment is a one-time injection under the retina. The goal is to see if it is safe and can slow or stop vision loss. The study involves 22 participants aged 4 and olde…
Phase: PHASE1, PHASE2 • Sponsor: Opus Genetics, Inc • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC